Novo Nordisk’s GLP-1 agonist Wegovy received accelerated FDA approval to treat metabolic dysfunction-associated steatohepatitis (MASH) in adults with non-cirrhotic liver scarring. Phase 3 results demonstrated improvement in liver fibrosis without disease worsening. This marks Wegovy as the first GLP-1 drug approved for MASH, potentially reshaping the therapeutic landscape alongside Madrigal’s Rezdiffra. While Wegovy’s approval may create competitive pressure for existing MASH therapies, it expands treatment options for a large patient population with unmet needs linked to obesity and metabolic dysfunction.